Key facts
- ALKEON CAPITAL MANAGEMENT LLC filed SCHEDULE 13G for Keros Therapeutics, Inc. Common Stock, par value $0.0001 per share (KROS).
- Disclosed ownership: 2.7%.
- Date of event: 31 Dec 2024.
ALKEON CAPITAL MANAGEMENT LLC - 31 Dec 2024 SCHEDULE 13G Report for Keros Therapeutics, Inc. Common Stock, par value $0.0001 per share (KROS)
- Filing Manager
- ALKEON CAPITAL MANAGEMENT LLC
- Reporting Manager
- Alkeon Capital Management LLC
- Symbol
- KROS
- Shares outstanding
- 40,777,778 shares
- Disclosed Ownership
- 1,101,000 shares
- Ownership
- 2.7%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 16:12:14 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Key filing fact
ALKEON CAPITAL MANAGEMENT LLC disclosed 2.7% ownership in Keros Therapeutics, Inc. Common Stock, par value $0.0001 per share (KROS) on 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:12.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Alkeon Capital Management LLC | 2.7% | 1,101,000 | 0 | 1,101,000 | /s/ Jennifer Shufro | Jennifer Shufro, Compliance Officer | |
| Panayotis D. Sparaggis | 2.7% | 1,101,000 | 0 | 1,101,000 | /s/ Panayotis D. Sparaggis | Panayotis D. Sparaggis, individually |
CIK / CUSIP context first